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INTRODUCTION 
 
The main objective of any drug therapy is to achieve a desired concentration of 
drug in blood or tissue, which is therapeutically effective and non-toxic for an extended 
period of time. This goal can be achieved by proper design of a sustained release dosage 
regimen. To achieve this, new technique may be applied to design novel drug delivery 
systems. 
 
Novel drug delivery systems2 can be broadly classified into two groups 
 
 Sustained release drug delivery system (SRDDS) 
 
 Controlled release drug delivery system (CRDDS) 
 
 SUSTAINED RELEASE DRUG DELIVERY SYSTEM (SRDDS) 
 
SRDDS   include any drug delivery system that achieves slow release of drug over 
an extended period of time. This leads to increase in duration of effect so that therapeutic 
effect is sustained. 
 
 CONTROLLED RELEASE DRUG DELIVERY SYSTEM (CRDDS) 
 
CRDDS has a meaning that goes beyond the scope of sustained action. It implies 
when the system is successful at maintaining constant drug levels in target tissue or cells. 
 
The ideal goal in designing a controlled release system is to deliver drug to the 
desired site at a pre-determined rate according to the needs of the body, i.e. a self regulated 
system based on feedback control. 
 
In general3, the dosing interval may be increased by any one of the following:  
1. By modifying the drug molecule to decrease the rate of elimination. 
2. By modifying the release rate of dosage form to decrease the                                                                           
    rate of absorption. 
 
3 
 
Both approaches seek to decrease fluctuations in plasma levels during multiple 
dosing allowing the dosing interval to increase without either overdosing or under dosing. 
 When attempts to extend the dosing interval by decreasing the rate of absorption, 
the formulation will be confronted with the physiological constraint of a finite residence 
time at the absorption site. Other factors which limit the designing of once a day dosage 
form are   
1. Plasma half life. 
2. Therapeutic index.  
3. Presence of absorption window. 
Only when the rate limiting step resides in the drug delivery system and not in 
physiological constraints, can control over drug administration be achieved. 
Controlled delivery attempts to: 
1. Sustained drug action at a predetermined rate by maintaining a relatively constant, 
effective drug level in the body with concomitant minimization of undesirable side 
effects associated with a saw tooth kinetic pattern. 
 
2. Localize drug action by spatial placement of a controlled release system (usually rate 
controlled) adjacent to or in the diseased tissue or organ. 
 
3. Target drug action by using carriers or chemical derivatization to deliver drugs to a 
particular “target” cell type. 
 
Figure no: 1 shows the comparative release of  
i) Conventional tablet 
ii) Sustained release tablet 
iii) Controlled release tablet 
 
In order to maintain a constant drug level in either plasma or target tissues, release rate 
from the controlled release system should be equal to the elimination rate from plasma or 
target tissue. The most conventional method to achieve a constant plasma level is the use 
of intravenous infusion. However, this would be inconvenient for most therapeutic 
situations so that other non-invasive routes such as the oral or transdermal route are 
preferred. 
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Figure No: 1 
Schematic representation of release pattern of Conventional drug delivery systems, 
SRDDS and CRDDS. 
 
Tablets: 
 
The oral route is the most popular route of drug administration. The duration of a 
drug after oral administration is mainly a function of drug related properties such as rate of 
absorption and clearance as well as residence time of the delivery system at the absorption 
site. Most sustained release drug delivery systems developed thus far, are aimed at slowing 
the apparent absorption rate by reducing the drug release rate from the dosage form. 
 
Because of limited residence time and possible existence an absorption window for 
some drug, control of gastrointestinal transit time and site specific release through specific 
binding of the drug delivery system to the absorption sites are attractive approaches to 
control and administration. With same expectations targeting of drugs is not the primary 
concern for most orally administered drugs. Rather, the aim is to increase the amount of 
drug delivered to, with concomitant prolongation in the general circulation. Hence, most 
systems employed are of the sustained release type. In cases, where systems are used to 
target a drug, the site of absorption rather than the site of action in targeted.  
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The following materials are used as retardants in matrix tablet formulations. 
Types of matrix tablets and materials used in matrix tablets: 
Matrix characteristics Materials 
 Insoluble, inert Polyethylene, PVC, Methacrylate 
copolymer, ethyl cellulose.  
 Insoluble, erodible Carnuba wax, Stearyl alcohol, Stearic acid, 
PEG, Castor wax, Triglycerides, PEG 
monostearate. 
 Hydrophilic Methyl cellulose, Hydroxy ethyl cellulose, 
HPMC, Sodium alginate, Galactomannose. 
 
The first class consists of retardants that form insoluble or skeleton matrices; the 
second class represents water insoluble materials that are potentially erodible; and the third 
class consists of polymers that form hydrophilic matrices. Loading doses are best included 
as the second layer of a two layer tablet or in coatings applied to the matrix core. 
 
Tablets may be directly compressed from mixtures of drug and ground polymer; 
however if ethyl cellulose is used as matrix former, a wet granulation method using ethanol 
can be used. The rate limiting step in controlling release from these formulations is liquid 
penetration into the matrix unless channeling agents are included to promote permeation of 
the polymer matrix by water, which allows drug dissolution and diffusion from the 
channels created in the matrix. 
 
Drug bioavailability which is critically dependent on the drug: polymer ratio may 
be modified by inclusion of other additives.  
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Design and fabrication of oral CRDDS: 
 
A sustained release oral dosage form usually consists of two parts: An immediately 
available dose to establish the blood level quickly and a constraining part that contains 
several times the therapeutic dose for protracted drug levels. Several approaches are 
available to add the immediately available portion to the sustaining part. Simple addition of 
non-sustained dose of drug to a capsule or tablet is the most direct method; Placement of 
the initial dose in the tablet coat with the sustaining the portion in the core represents an 
alternative approach. The heart of the system, nevertheless resides with the sustaining 
portion of the dosage form. 
 
Potential physiological methods that can be used to retard drug release are: 
 
 Capsules of polymeric material filled with a solid or liquid drug in which drug release 
is controlled by diffusion through the capsule wall. 
 A heterogeneous disruption of drug particles in a solid matrix which can be either 
biodegradable or non-biodegradable and which controls drug release by diffusion 
through the matrix, by erosion of the matrix, or by a combination of both diffusion and 
erosion. 
 A laminate of agent and polymeric material made by coating a film of biodegradable or 
non-biodegradable material with solid drug and then by forming the film into a sealed 
“sandwich” or “ jelly roll”, in which drug release is by diffusion , erosion or both.  
 A heterogeneous dispersion or solution of drug in a water swellable hydrogel matrix, 
which controls drug release by slow surface-to-center swelling of the matrix by water 
and subsequent diffusion of the drug from the water- swollen part of the matrix. 
 Liquid- liquid encapsulation of the drug in a viscous solution of polymer, which 
controls drug release by slow diffusion through dilution of the medium. 
 Pumps that either mechanically or chemically (osmotic pressure) provide drug in a 
controlled manner. 
 Drug coated micro pellets which have an apparent density lower than that of gastric 
secretions. Thus, the final product floats on gastric secretions for an extended period, 
while slowly releasing drug. 
 Drug contains bioadhesive polymers that adheres to the mucin coating of the 
gastrointestinal tract and which is retained on the surface epithelium to extend 
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gastrointestinal transit time of the drug. Drug is released at a constant rate from the 
bioadhesive polymer for subsequent absorption. 
 Chemical bonding of a drug to polymer back bone by pendent amide or ester linkages, 
which controls the drug release by hydrolysis. 
 Formation of macromolecular structures of the drug via ionic or covalent linkages, 
which controls drug release by hydrolysis, thermodynamic dissociation or microbial 
degradation.  
 
The majority of oral controlled release systems rely on dissolution, diffusion or a 
combination of both mechanisms to generate slow release of drug to the gastrointestinal 
tract. 
 
Factors influencing the design and performance of the sustained release / controlled 
release products4: 
 
1. Drug properties:  
 
The physicochemical properties of a drug includes stability, solubility, partition 
characteristics, pH, dissociation constant charge and protein binding propensity play a 
dominant role in the design and performance of controlled release systems. 
 
2. Routes of drug delivery: 
 
The drug delivery systems in certain routes of administration can exert a negative 
influence on drug efficacy particularly during chronic administration and hence other 
routes of administration should be considered. Performance of controlled drug release 
systems may also influenced by physiological constraints imposed by a particular route 
such as first pass metabolism, gastrointestinal motility, blood supply.  
 
3. Target sites:  
 
In order to minimize the unwanted side effects, it is desirable to maximize the 
fraction of applied dose reaching the target organ or tissue. This can be partially 
achieved by local administration or by the use of a carrier. 
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4. Acute or chronic therapy:  
 
Consideration of whether one expects to achieve cure or control of a condition and 
the expected length of drug therapy are important factor in designing controlled drug 
delivery system. Attempts to generate one year contraceptive implant present 
significantly different programs in design than does an antibiotic for acute infection. 
 
5. Disease:  
 
Pathological changes during the course of a disease can play a significant role in 
the design of suitable drug delivery systems. 
For example, in attempting to design an ocular controlled release product for an 
external inflammation, the time course of changes in protein content in cellular fluids 
and in the integrity of the ocular barriers would have to be taken into considerations. 
 
6. Patient: 
 
Whether the patient in ambulatory or bedridden, young or old, obese or gaunt etc, 
can influence the design of a controlled release product. In implant or intramuscular 
injection of a drug to a bedridden patient with little muscle movement may perform in 
a manner significantly different from that of an ambulatory patient. 
 
ADVANTAGES OF SRDDS AND CRDDS: 
 Patient compliance. 
 Minimize drug accumulations with chronic dosing. 
 Minimize or eliminate local and systemic side effect. 
 Improve efficiency in treatment by controlling the condition more promptly reduce the 
fluctuation in plasma drug level. 
 Targeting the drug material towards tissues or organs or site of action. 
 Prolongation of drug action. 
 Precise control of response to ultra short acting drugs. 
 Avoidance of first pass metabolism. 
 Absorption rate independent of environmental conditions. 
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DISADVANTAGES OF SRDDS AND CRDDS ARE: 
 Over dosing due to dose dumping by drug release. 
 Sub-optimum bioavailability. 
 Less flexibility in dosage adjustments. 
 Prompt termination of therapy is not possible. 
 High cost. 
 Un predictable and often poor in vitro-in vivo correlation. 
 Variability in drug levels. 
 
However, in properly designed delivery system these negative aspects can be 
minimized to an acceptable level. 
 
Drugs that are not suitable for SRDDS / CRDDS are: 
 
 Drug with long biological half-life. 
 Drugs with a narrow requirement for absorption. 
 Drugs which are not effectively absorbed in the lower intestine. 
 Drugs which are insoluble and whose availability is controlled by dissolution. 
 
ORAL SUSTAINED RELEASE DRUG DELIVERY SYSTEMS5: 
 
The basic concept underlying the design of oral sustained release the drug delivery 
system is to maintain a steady therapeutic drug level over a period of 12-24 hrs. 
 
Different types of the oral sustained dosage forms: 
Most of the oral sustained release dosage forms can be classified as follows: 
 Single units (matrix tablets, coated tablets and spansules). 
 Multiple units (granules, beads, micro capsules and micro spheres). 
 Inert insoluble matrix. 
 Hydrophilic gel matrix. 
 Ion exchange resins. 
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Single and Multiple units:  
 
The choice between the single unit and multiple units would depend upon the drugs 
and desired release pattern. For example, multiple units will exhibit less. Variable 
performance, especially for the enteric coated products. However, the small tablets 
(<2mm) in the presence of food are retained in the stomach for a much shorter time than 
the large tablets. The gastrointestinal time therefore, would be an important factor to 
consider in selecting a type of dosage form in relation to the duration of drug release and 
available performance. 
 
Insoluble matrix tablets: 
 
Inert insoluble matrix tablets are prepared from insoluble waxes such as carnuba 
wax, bees wax, and polymers like ethyl cellulose, cellulose acetate, stearyl alcohol and 
stearic acid are widely utilized in the sustained release formulation. 
 
Hydrophilic matrix dosage formulations: 
 
They are usually made up of cellulose, carboxy vinyl polymers, acrylate and 
methacrylate polymers. 
 
Other dosage forms like coated tablets, spansules, granules, microcapsules and ion 
exchange resins are prepared by using various microencapsulation techniques. 
 
In matrix devices, the solid drug is dispersed in an insoluble matrix. The rate of 
drug released is dependent on the rate of drug diffusion but not on the rate of solid 
dissolution.  
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The appropriate equation describing drug release from this system is as following. 
 
Q = [Dε/T (2A- εCs) Cst] ½ 
Where; 
 
Q – Weight in gm of drug released per unit surface area. 
D – Diffusion co-efficient of drug in the release medium. 
Ε – Porosity of matrix. 
T – Totuosity of the matrix. 
Cs – Solubility of the drug in the release medium. 
A – Concentration of drug in tablet (g/ml). 
 
The assumptions to derive the above equation are as follows: 
 
1. A pseudo-steady state is maintained during release. 
2. A >> Cs i.e, excess solute is present. 
3. C = 0 in solution at all times (perfect sink). 
4. Drug particles are much smaller than those in the matrix. 
5. The diffusion co-efficient remains constant. 
6. No interaction between the drug and the matrix occurs. 
For purposes of data treatment, the equation is reduced to  
 
                              Q = Kt1/2 
 
Therefore the plot of amount of drug released versus the square root of time should 
be linear if drug release from the matrix is diffusion controlled. 
 
As in the reservoir device, it is often necessary that a portion of the drug be 
released quickly for immediate absorption. This is usually accomplished by placing the 
initial dose in the coat of the tablet. The coat and matrix can be tableted together by press-
coating. In non-coated systems, the initial dose is simply tableted with the sustaining dose. 
 
The three major types of matrix diffusion control devices are insoluble plastic, fatty 
and hydrophilic matrices. However, there are problems that arise from chewing an 
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insoluble matrix. If the drug was contained within pores and channels of a polymeric 
matrix following compression, then upon mastication the drug would be released very 
quickly. This could be dangerous in the case of drugs with a narrow therapeutic index. 
 
In this drug delivery system, the drug is homogenously dispersed as discrete 
crystals or solid particles in a matrix environment formed by the cross-linking of linear 
polymer chains. The drug molecules elute out of the matrix only by dissolution in and then 
by diffusion through the polymer structure. The drug solids in the layer closer to the 
surface of the device are the first to elute, and when this layer becomes exhausted, the drug 
solid in the next layer begins to get depleted.  
 
Figure No: 2  
Schematic representation of drug dissolution. 
 
 d (δp) δp δd 
  
  
 Drug C’p 
 Dispersion zone                                      Perfect          
 Cp solution  
 A sink 
 Cd  Cb 
                          Dissolved drug region 
 
                               
Where; 
A – Initial amount of drug solids impregnated in a unit volume of  polymer matrix. 
Cp – solubility of drug in polymer phase. 
C’p – concentration of drug at polymer/solution interface. 
Cd - concentration of drug at solution/ polymer interface. 
Cb - concentration of drug in the bulk of elution solution. 
δp& δd- thickness of drug depletion zone in the matrix and of the   
      Hydrodynamic layer on the immediate surface of the device. 
d (δp) - differential thickness of depletion zone formed after more drug solid elute out. 
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Advantages: 
 
1. A unique dual release mechanism ensures complete release of the active 
ingredients. 
2. A high yield is obtained and tablets have elegant properties. 
3. Extended day time and night time activity of the drugs. 
4. Potential for reduced incidence of side effects. 
5. Reduced dose frequency. 
6. Increased patient compliance. 
  
Disadvantages: 
 
1. Not applicable to liquids. 
2. Potential gastrointestinal side effects.  
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LITERATURE REVIEW 
 
 Pabon et al (1992)6, has studied the dissolution rates of mixed controlled release 
matrix tablets containing hydroxy propyl methyl cellulose  and polyamide 12 for 
metaclopromide hydrochloride and a reference tablet using cellulose microcrystalline 
as excipient and has concluded that dissolution kinetics were markedly different for the 
different formulations studied depending upon the proportions of excipients.   
 
 Sheu et al (1992)7, has studied the effects of the media on the dissolution of diclofenac 
sodium from voltaren and hydroxy propyl methyl cellulose matrix tablets and has 
concluded that drug release from hydroxy propyl methyl cellulose matrices was non-
Fickian in all media and also concluded that diclofenac release from hydrophilic and 
hydrophobic tablets is dependent on the dissolution media. 
 
 Pabon et al (1994)8, has studied the fracture and dissolution rates of matrix tablets 
prepared with hydroxy propyl methyl cellulose and polyamide 12 at different 
proportions using metaclopromide hydrochloride as model drug and has concluded that 
the dissolution rates was different for each formulation and depended on the specific 
polymer percentage. 
 
 Dong et al (1996)9, has studied the effect of hydroxy propyl methyl cellulose on the 
mechanism of soluble drug release from hydrophilic matrix tablets prepared with 
captopril and albuterol sulfate and confirmed that the drugs were released by non-
Fickian diffusion mechanism and concluded that the different contents of hydroxy 
propyl methyl cellulose in the matrices only affected Higuchi release patterns.  
 
 Sung et al (1996)10, has studied the effect of hydroxy propyl methyl cellulose and 
lactose ratio and hydroxy propyl methyl cellulose viscosity grade on the release of a 
model drug, adinazolam mesylate and hydroxy propyl methyl cellulose from a hydroxy 
propyl methyl cellulose matrix tablet and concluded that with higher drug and polymer 
release rates found for formulations with lower polymer lactose ratio and lower 
polymer viscosity grades. 
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 Vazquez et al (1996)11, has studied the potential value of hydroxy propyl methyl 
cellulose mixture as gelling agents in matrix tablets for hydro soluble drugs and the 
relationship between the gelling agent viscosity and the kinetics of drug release from 
atenolol hydrophilic matrix tablets and has concluded that all drug s release was 
diffusion limited. 
 
 Dortunc et al (1997)12, has studied the effect of polymer grade, influence of the 
additive magnesium stearate and lactose, particle size and pH of dissolution medium on 
the release of acetazolamide from a controlled release swellable tablets prepared by 
direct compression and found that hardness slightly increased with increasing the 
amount of hydroxy propyl methyl cellulose drug release decreased when the polymer 
amount was increased. 
 
 Traconis et al (1997)13, has prepared the matrix tablets containing metronidazole and 
10% of polymer, different proportions of sodium carboxy methyl cellulose plus 
hydroxy propyl methyl cellulose  or ethyl cellulose plus hydroxy propyl methyl 
cellulose and studied the release of metronidazole from tablet in acidic medium and 
found that the addition of sodium carboxy methyl cellulose produced biphasic linear 
kinetics, before and after the transition point, increasing in concentration of sodium 
carboxy methyl cellulose resulted in decreasing dissolution rates. 
 
 Relasco et al (1999)14, has studied the influence of drug : hydroxy propyl methyl 
cellulose ratio, drug and polymer particle size and compression force on the release of 
diclofenac sodium from hydroxy propyl methyl cellulose tablets and observed that the 
rate and mechanism of drug release matrices were mainly controlled by the drug: 
polymer ratio, the drug and polymer particle size influence on the drug release 
parameters and found that compressional force influence only on lag time. 
 
 Heng et al (2001)15, has studied the influence of mean hydroxy propyl methyl cellulose 
particle size and number of polymer particles on the release of aspirin from swellable 
hydrophilic matrix tablets by preparing the tablets with different concentrations of 
different size fractions of hydroxy propyl methyl cellulose as well as lactose and 
magnesium stearate and has concluded that the release of aspirin from matrix tablet 
formulations increased markedly when hydroxy propyl methyl cellulose particle size 
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was greater than 113µm and release rate was much less sensitive to changes in hydroxy 
propyl methyl cellulose particle size below 113µm.  
 
 Rao et al (2001)16, has studied the effect of SBE 7M-beta-cyclodextrin as a 
solubilizing agent on prednisolone, a poorly water soluble drug, release from hydroxy 
propyl methyl cellulose matrix tablets and found that there is enhanced drug release to 
a control formulation, prepared using lactose instead of SBE 7M-beta-cyclodextrin. 
 
 Shiva kumar et al (2001)17, has studied the effect of hydroxy propyl methyl cellulose 
and hydroxy ethyl cellulose on release of the cetostearyl alcohol embedded diclofenac 
sodium from tablets for controlled release and found that hydroxy propyl methyl 
cellulose and hydroxy ethyl cellulose was showing differences in their behavior in 
controlling the release of diclofenac sodium. 
 
 Obadiat AA et al (2002)18, has studied the release of dextro methorphan hydrobromide 
DM-HBR) from matrix tablets containing sodium CMC and hydroxy propyl methyl 
cellulose and found that the results obtained indicated that the nonionic hydroxy propyl 
methyl cellulose had little retarding effect on drug release from the matrix, anionic 
sodium CMC significantly reduced the release rate of the drugs. An effect which was 
attributed to interaction between the drug and sodium CMC due to formation of 
insoluble complex. The pH affected both the solubility of the drug and die erosion rate 
of the matrix. Combination of both HPMC and sodium CMC in optimum proportions 
would result in a near zero order release. 
 
 Reynolds et al (2002)19, has studied the effect of tablet surface area and/or volume on 
drug release from matrix tablets containing hydroxy propyl methyl cellulose using 
soluble drugs (Promethazine hydrochloride, Diphenhydramine hydrochloride, and 
proponalol hydrochloride) by comparing the drug release from tablets having similar 
values of surface area and/or volume within the same tablet shape and among different 
shapes and has concluded that surface area and/or volume is one of the key factor in 
controlling the drug release from hydroxy propyl methyl cellulose matrix tablets. 
 
 Sapna et al (2002)20, prepared venlafaxine hydrochloride sustained release tablets by 
using matrix system based on swellable and no swellable polymers such as hydroxy 
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propyl methyl cellulose, ethyl cellulose, cellulose acetate and eudragit RSPO were 
selected. Combinations of non swellable polymers were also studied with hydroxy 
propyl methyl cellulose for sustained release up to 16 hours. The effect of drug to 
polymer in vitro release was studied. 
 
 Al taani BM et al (2003)21, prepared pH dependent swellable and erodible-buffered 
matrix tablets by using hydrophilic polymers HPMC and pH dependent solubility 
polymer(eudragit L100-55) with different micro environment pHs. Diclofenac sodium 
was chosen as choice of drug. The swelling and erosion matrices containing only 
hydroxy propyl methyl cellulose and eudragit L100-55 were studied in phosphate 
buffer solution of pH similar to the microenvironment pHs of the matrices and found to 
be the drug release is linear as a function of time (amount of drug released was found 
to be higher in the medium of pH 7.4 than that of pH 5.9).  
 
 Amaral MH et al (2003)22, has studied the effect of water soluble carriers on naproxen 
release from hydrophilic matrix tablets and found that the release profile of naproxen 
from hydroxy propyl methyl cellulose  matrices remained unchanged when lactose and 
PEG-4000 were added to the same drug and polymer concentrations due to the higher 
water solubility of PEG-4000, the erosion of compressed mixtures of hydroxy propyl 
methyl cellulose  k-100M/ PEG-4000(1:1)was higher than the erosion of tablets 
containing the same proportion of lactose. 
 
 Chowdary KP et al (2003)23, have prepared mucoadhesive matrix tablets employing 
sodium CMC, hydroxy propyl methyl cellulose and EC using diltiazem as a model 
drug. Tablets formulated employing sodium CMC with 5% EC gave slow and 
complete release over a period of 12 hrs. These tablets exhibited good mucoadhesion in 
the intestine for 10-12 hrs in the X-Ray studies. Non-Fickian release was observed 
from most of the formulations ( A two layer tablet formulation, an immediately 
releasing layer consisting of diltiazem and croscarmellose sodium (A super 
disintegrate) and a matrix consisting of diltiazem, sodium CMC and EC as a second 
maintenance  layer, gave release close to the theoretical sustained release (SR) needed 
for diltiazem. 
 Gohel MC et al (2003)24, has prepared pH independent sustained release matrix tablets 
by using rate controlling polymers such as eudragit RSPO/ RlPO, HPMCK4M. 
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Verapamil hydrochloride was chosen as model drug. Tablets were prepared by wet 
granulation method and succinic acid and KH were incorporated in the matrix in order 
to obtain pH independent drugs release. They found that the required release rate 
obtained with low level of eudragit RSPO/RLPO (30% w/w), low level of HPMC K4M 
(- 10% w/w), high level of PEG 4000 (15% w/w) and desired drug release pattern can 
be obtained by adopting a systemic formulation approach. 
 
 Samani SM et al (2003)25, has studied the effect of polymer blends of hydroxy propyl 
methyl cellulose (viscosity grades 60 and 500mpas), carbopol-940 on release profile of 
diclofenac sodium from matrices and found that when hydroxy propyl methyl cellulose 
viscosity grade (60 mpas) at higher polymer drug ratio (more than 0.8:1). The Carbopol 
can extend the release time appreciably best release profile have fluctuations. When an 
appreciate blend of hydroxy propyl methyl cellulose and Carbopol was used the drug 
release became more uniform and it’s kinetic approached to zero order and release 
fluctuations were diminished. 
 
 Vostalova L et al (2003)26, has formulated hydrophilic matrix tablets by using hydroxy 
propyl methyl cellulose and other cellulose derivatives and chosen well soluble 
diltiazem chloride and badly soluble ibuprofen as model drugs. Evaluated and found 
that the formulation and manufacture variables can influence the rate of drug release 
from matrix. Higher solubility of the drugs and lower solubility of compacts resulted in 
more rapid release of the active ingredient and lower concentrations of hydroxy propyl 
methyl cellulose  accelerates release of both drugs. 
 
 Bravo SA et al (2004)27, has formulated the swellable matrices for the controlled 
release of diclofenac sodium by using hydroxy propyl methyl cellulose  and carboxy 
polymer (carbopol-934) as rate controlling polymers and studied for the influence of 
polymer content, the polymer ratio, the polymeric swelling behavior and pH changes 
on the release rate of diclofenac sodium. Combination of these two polymeric matrix 
formers resulted in near zero order release rate of diclofenac sodium. The diclofenac 
release from matrix tablets was pH dependent, being markedly reduced at lower pH 
(could be attributed to the poor solubility of diclofenac sodium at this pH values) in 
0.1N HCl solution, HPMC controlled drug release. As the pH increases, both hydroxy 
propyl methyl cellulose and Carbomer controlled release occurs, as a result of 
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Carbomer became ionized being able to interact with hydroxy propyl methyl cellulose  
to control drug release. 
 
 Martinez Gonzelez et al (2004)28, has formulated matrix tablets using hydroxy propyl 
methyl cellulose as rate controlling polymer and 4-amino pyridine was chosen as 
model drug and studied for the influence of enteric coated lactose on the release profile 
from hydroxy propyl methyl cellulose matrix tablets were prepared by wet granulation 
method and found that decreasing release constant values were observed with 
increasing enteric coated lactose concentrations up to 9%. This is attributing to an 
increasing obstruction of the diffusion path by isolated enteric coated lactose particles 
that are insoluble in HCl and/or surrounded by a water filled space. After a critical 
enteric coated lactose concentrations, the water filled spaces surrounding enteric coated 
lactose particles percolate, producing opposite effect, increasing release constant as the 
enteric coated lactose proportion increases from 10-50%. 
 
 Cao QR et al (2005)29, have studied the effect of pharmaceutical excipients on the in 
vitro release profiles and the release mechanism of monolithic hydroxy propyl methyl 
cellulose (4000Cps) matrix tablets  (m-HPMC), in terms of mimicking the dual drug 
release character of bi layered tylenol-SR tablets was studied and acetaminophen was 
used as the model drug. The m-HPMC tablets were prepared using wet granulation 
method followed by direct compression. Release profile and swelling rate of m-HPMC 
tablets were found to be highly influenced by the types and amounts of pharma 
excipients incorporated. Starch -1500 and sodium lauryl sulphate played a key role in 
determining the dissolution rate of m-HPMC tablets. Additional excipients i.e. MCC 
and sodium di hydrogen phosphate used to tune the release profile of m-HPMC tablets. 
The effect of excipients on the drug release from HPMC based matrix tablets was 
found to be mainly due to a change in hydrophilic gel expansion and on physical 
interaction between the drug and HPMC. 
 
 Genc L et al (2005)30, has prepared sustained release matrix tablets using different 
polymers such as hydroxy propyl methyl cellulose, carbopol-934 and eudragit-RL /PO 
by direct compression technique. Clarithromycin was chosen as model drug and 
evaluated for influence of polymer type and concentration on drug release from matrix 
were investigated by 23 factorial designs and found that tablets containing hydroxy 
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propyl methyl cellulose, carbopol-934 and eudragit-RL/PO were found suitably to 
sustained drug release. 
 
 Peng HL et al (2005)31, has formulated SR matrix tablets using carbopol-71G and m-
HPMC and selected hydrochlorthiazide as model drug and studied for factors 
influencing dissolution rate. Tablets were prepared by wet granulation method. The 
factors affecting the drug release behaviors from the matrix tablets included the 
quantity of HPMC and carbopol-71G, tablet hardness, pH environment of the 
dissolution media paddle rotating speed. 
 
 Srivathsva AK et al (2005)32,  has formulated floating matrix tablets to prolong gastric 
residence time and to increase drug bioavailability and tablets prepared by direct 
compression method by using polymers such as hydroxy propyl methyl cellulose (K-
15M and K-4M), guar gum and the sodium CMC- based matrix tablets showed greater 
swelling indices. The tablets exhibited controlled and prolonged drug release profile 
while floating over the dissolution medium. 
 
 Pan WS et al (2005)33,  has formulated acipimox sustained release matrix tablets by 
using hydroxy propyl methyl cellulose  as a drug release retarding material and 
evaluated for the factors effecting the acipimox release rate from matrix including 
types and quantity of hydroxy propyl methyl cellulose  and additives, and 
manufacturing procedures were evaluated and found that the types and quantity of 
hydroxy propyl methyl cellulose  used in matrixes and the tablet surface area were 
closely associated with the acipimox release and the types and quantity of additives and 
manufacturing procedure(eg: dissolution apparatus rotating speed) showed low 
significant effect on acipimox release. The diffusion factor place a main role in the 
entire dissolution slow release of drugs obeys Non-Fickian diffusion mechanism. 
 
 Vueba ML et al (2005)34, has studied the influence of different cellulose ether 
polymers such as release rate of ibuprofen from hydrophilic matrix tablets [methyl 
cellulose (MC 25), Hydroxy propyl cellulose (HPC) and HPMC (K 15M and K 
100M)]. In addition the influence of diluents- lactose mono hydrate (LAC) and small 
be cyclodextrin(b-CD) was evaluated, polymers MC-25 and HPC were found to be 
unsuitable for the preparation of this kind of solid dosage forms, while hydroxy propyl 
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methyl cellulose  K-15M and K-100M showed to be advantageous. The highest MDT 
(mean dissolution time) obtained with hydroxy propyl methyl cellulose indicating 
higher drug retarding ability of the polymer. The release process was also found to be 
slightly influenced by the kind of diluents used. 
 
 Harish NM et al (2006)35, has developed sustained matrix tablets by using hydroxy 
propyl methyl cellulose, eudragit RLPO as rate controlling polymers. Terbutaline 
sulphate was chosen as model drug. Tablets were prepared by wet granulation method 
and evaluated for flow properties of granules, compressibility index, swelling index 
and drug content and in vitro studies for drug release and found that granules showed 
that satisfactory flow properties, compressibility and drug content. The optimized 
formulation could extend release up to 12 hrs and these optimized formulations showed 
similar release profile as that of the marketed formulation. 
 
 Haremath SN et al (2007)36, has formulated metformin hydrochloride matrix tablets 
by using different viscosity grades and ratios of hydroxy propyl methyl cellulose and 
evaluated mainly to assess the effect of drug polymer ratio and hydroxy propyl methyl 
cellulose viscosity grade and the release of drug from hydrophilic matrices and found 
that the lower viscosity grade polymer showed a rapid drug release from the matrices 
than the higher viscosity grades. The higher drug polymer ratio showed a greater drug 
release than the others. 
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AIM & OBJECTIVE OF THE WORK 
 
Viloxazine is a bicyclic antidepressant morpholine derivative that acts as a selective 
norepinephrine reuptake inhibitor (NRI). It is a racemic compound with two stereoisomers, 
the (S)-(–)-isomer being five times as pharmacologically active as the (R)-(+)-isomer. 
Recommended daily dose is 100mg in two or three divided doses. If necessary, it may 
increase up to 150mg. Due to its low biological half life it requires frequent administration, 
hence extended release dosage forms are formulated to reduce dosing frequency thereby 
improving patient’s compliance. 
 
The main objective of this work is to formulate sustained release matrix tablets by 
adopting wet granulation method using HPMC, HCO and EC as retarding materials at 
different concentrations. All the formulations are to be assayed for drug content and in 
vitro release for the best amongst these formulations. 
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DRUG PROFILE 37, 38,39,40,41 
 
Name: 
 
       Viloxazine Hydrochloride    
 
Category: 
 
     Anti-depressant 
 
Structure:        
                                  
 .HCL  
 
Chemical name: 
 
 (RS)-2-[(2-ethoxyphenoxy) methyl] morpholine 
 
Molecular formula: 
 
 C13H19NO3 HCL 
 
Molecular weight: 
 
 273.8 
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Characteristics:- 
 
Appearance: 
  
 White to off-white crystalline powder. 
 
Solubility: 
 
 Soluble in Acetic acid, Methanol and Water. 
 
Standards: 
 
          Viloxazine Hydrochloride contains not less than 95.0% w/w and not more than 
105%w/w of C13H19NO3 (Calculated with reference to anhydrous substance). 
 
Therapeutic uses: 
 
   Viloxazine Hydrochloride is used in the treatment of depression. 
 
Mechanism of action:  
 
 It is a Nor-adrenaline reuptake inhibitor (NRI).  
 It also weakly inhibits the dopamine re-uptake. 
 It is also reported to have little affinity for Muscarinic, Histaminirgic or α1-adrenergic 
receptors. 
 
Pharmacokinetics:- 
 
Absorption: 
 
 The drug is readily absorbed from the GIT. Following oral administration, it 
undergoes extensive first pass metabolism in the liver mainly to the active metabolite 
O-desmethyl Viloxazine. Peak plasma concentrations of Viloxazine and O-desmethyl 
Viloxazine appear about 2 and 4 hours after administration respectively. 
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Distribution: 
   
Protein bindings of Viloxazine and O-desmethyl Viloxazine are low. 
(Approximately 25%). 
 
Metabolism: 
  
 The drug following oral administration, it undergoes extensive first pass 
metabolism in the liver mainly to the active metabolite O-desmethyl Viloxazine. 
Formation of O-desmethyl Viloxazine is mediated by the CytochromeP-450 isoenzyme 
CYP2D6. Other metabolites include N-desmethyl Viloxazine and N, O-di desmethyl 
Viloxazine. 
 
Elimination: 
 
 The mean plasma elimination half life of Viloxazine and O-desmethyl Viloxazine 6 
and 8 hrs respectively. Viloxazine is excreted predominantly in the form of its 
metabolites, either free or in conjugated form, about 2% is excreted in the faecus. 
 
     Side effects: 
 
Nausea, Dizziness, dry mouth, Sexual dis-function, may cause sustained rise in BP, 
needs BP monitoring. 
 
Precautions: 
 
 It should be used with caution in those with history of myocardial infraction or 
unstable heart disease. 
 It should also be used with caution in patients with a history of epilepsy and should 
be discontinued in any patient developing a seizure. 
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Drug interaction: 
 
Viloxazine is known to increase plasma levels of phenytoin by an average of 
37%.It is also known to significantly increase plasma levels of theophylline and 
decrease its clearance from the body, sometimes resulting in accidental overdose of 
theophylline. 
 
Availability: 
  
 Available in the form of conventional tablets, extended release tablets and capsules.  
 
Packaging and Storage: 
 
 Store in air tight container and protected from light. 
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Marketed Brand Names: 
 
1. Vivalan SR tablets. 
 
2. Emovit XR capsules. 
 
3. Vivarint CR tablets. 
 
4. Vicilan XR capsules. 
 
 Austria: Vivarint;  
 
 Belgium: Vivalan; 
  
 Czech Republic: Vivalan; 
 
 France: Vivalan;  
 
 Germany: Vivalan; 
  
 Italy: Vicilan; 
 
 Portugal: Vivalan; 
  
 Spain: Vivarint; 
  
 United Kingdom: Vivalan; 
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EXICIPIENTS PROFILE 
 
 
HYDROXY PROPYL METHYL CELLULOSE42 
 
Synonyms: 
 
          Cellulose,  Hydroxy  propyl  methyl ether,   Culminal   MHPC, E464, Methocel, 
HPMC, Methyl cellulose propylene glycol ether, Methyl hydroxy propyl cellulose, 
Metolose, Pharmacoat. 
 
Chemical name: 
 
Cellulose 2- hydroxy propyl methyl ether. 
 
Empherical formula: 
 
O-methylated and O-(2- hydoxypropylated) cellulose. 
 
Molecular weight: 
 
10000 - 1500000  
 
Description: 
 
          It is odorless, tasteless, white or creamy-white colored fibrous or granular powder. 
 
Pharmaceutical specifications:- 
 
pH: 
 
5.5 to 8.0(1 %w/w solution). 
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Solubility: 
 
Soluble in cold water forming viscous colloidal solution, in mixtures of ethanol and 
dichloromethane, mixtures of methanol and dichloromethane.  Practically insoluble in 
chloroform, ethanol, ether. 
 
Melting point: 
 
190-2000C 
 
Moisture content: 
 
It absorbs moisture from atmosphere. 
 
Specific gravity: 
 
    1-26 
 
Stability: 
 
          It is stable, although it is hygroscopic after drying. It is stable between pH 3 – 11. 
Increasing temperature reduces viscosity. Aqueous solutions are enzyme resistant but 
prone to microbial spoilage. HPMC powder should be stored in a well closed container, in 
a cool dry place. 
 
Incompatibility: 
 
          It is incompatible with some oxidizing agents. It doesn’t complex with any metallic 
salts and inorganic compounds forming insoluble precipitates. 
 
Safety: 
          It is non-toxic and non-irritant, but excessive oral consumption has laxative effect. 
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Applications in pharmaceutical formulations or technology: 
 
  In tabletting technology, 2–5% w/w is used as binder and 2–   10% w/w of polymer is 
used in film coating. Higher viscosity grades may be used in matrix tablet to retard the 
water soluble drug release. 
 
 In ophthalmic preparations, it is used as thickening and   suspending agent. 
 
 In topical gels and ointments, used as emulsifier, suspending and stabilizing agent. 
 
 Used as film former in tablet dosage form. 
 
HYDROGENATED CASTOR OIL42 
 
Non proprietary names: 
 
USPNF: hydrogenated castor oil. 
 
Synonym: 
 
Castor wax, Castor wax MP70, Castor wax MP80, Opal wax, Simulsol. 
 
Chemical name: 
 
Glyceryl-tri-(12- hydroxy stearate) 
 
Empherical formula: 
 
C55O9H110  
 
Molecular weight: 
 
939.50 
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Functional category: 
 
 Extended release agent, stiffening agent, tablet and capsule lubricant. 
 
Description: 
 
 It occurred as white color powder or flakes. 
 
Properties:- 
 
Melting point range: 
 
            85- 88°C 
 
Specific gravity: 
 
            1.023 
Moisture content: 
 
                      ≤ 0.1 % 
 
Solubility: 
 
 Insoluble in water, soluble in acetone and chloroform. 
 
Incompatibilities: 
 
It is compatible with most natural vegetable and animal waxes. No 
incompatibilities are reported in the literature. 
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Stability and Storage: 
 
 It is stable at temperature up to 1500C. Clear stable chloroform solutions containing up 
to 15 % w/v of hydrogenated castor oil may be produced. 
 
 It may also be dissolved at temperatures greater than 900C. 
 
 Store in a well closed container in a cool dry place. 
 
Application in pharmaceutical field: 
 
 It has hard, high melting point range which is used in oral and topical pharmaceutical 
formulations. 
 
 In oral formulations, it is used to prepare sustained release tablets and capsule 
preparations. It is used as a coat or to form a solid matrix. It is additionally used to 
lubricate the die walls of tablet presses. It is also used in cosmetics. 
 
 In topical formulations, it is used to provide stiffness to creams and emulsions. 
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ETHYL CELLULOSE42 
 
Synonyms:  
 
 Aqua coat, E462, Ethocel, Surelease. 
 
Chemical name: 
 
 Cellulose ethyl ether. 
 
Functional category: 
 
 Coating agent, tablet binder, viscosity increasing agent. 
 
Description: 
  
 Ethyl cellulose is a tasteless, free flowing white to light tan coloured powder. 
 
Properties:- 
 
Density: 
 
 0. 4 g/cm3 
 
Glass transition temperature:  
 
 130-133oC 
 
Hygroscopicity:  
 
 Absorbs very little water at high relative humidity.  
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Solubility:  
 
 Practically insoluble in glycerin, propylene glycol and water. Freely soluble in 
chloroform, ethanol, methanol, toluene, methyl acetate, tetrahydrofuran and in mixture of 
aromatic hydrocarbon with ethanol 95%. 
 
Specific gravity:  
 
 1.12-1.15 
 
Incompatibilities: 
 
Incompatible with paraffin wax & microcrystalline wax. No incompatibilities are 
reported in the literature. 
 
Storage condition: 
 
Ethyl cellulose is a stable, slightly hygroscopic material. It should be stored in a dry 
place, in a well-closed container at a temperature between 7-32°C.  
 
Applications in pharmaceutical field: 
 
 It is used as a coating agent for hygroscopic tablets and granules. It is used to 
modify the release of a drug to improve the stability of formulation. 
 
POLYVINYL PYRROLIDONE (PVP K-90)42: 
 
Polyvinyl pyrrolidone is white creamy white, odorless, hygroscopic powder. It is 
used as tablet blender, suspending agent or viscosity increasing agent. In tabletting, PVP 
solutions are used as binders in wet granulation process. PVP is also added to powder 
blends in the dry form and granulated to situ by the addition of water, alcohol PVP 
solutions may also be used as coating agent. It is incomplete in solution with a wide range 
of inorganic salts, natural and synthetic resins and other chemicals. The efficacy of some 
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preservatives, eg: thiomersol may be adversely affected by the formulation of complexes 
with PVP. 
 
MAGNESIUM STEARATE42: 
 
 It is fine white, precipitated or milled, impalpable powder with faint characteristic 
odor and greasy to touch, it is slightly soluble in warm benzene and warm ethanol but 
insoluble in water and ether. It is used as lubricant in capsules and tablet granules. 
 
TALC42: 
 
 Talc is purified, hydrated, magnesium silicate but may contain small amount of 
aluminium silicate and iron. It is a very fine powder, which is white to grayish white 
colored, odorless, impalpable and crystalline. It is widely used as a lubricant in oral solid 
dosage forms. 
 
COLLOIDAL SILICON DIOXIDE42: 
 
 Colloidal silicon dioxide is submicroscopic fumed silica, with a particle size of 
about 15 nm. It is a light, loose, bluish-white colored, odorless, tasteless, non gritty 
amorphous powder. It is used as a glidant to improve the flow properties of dry powder in 
tabletting. 
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ISOPROPYL ALCOHOL42 
 
Synonym:  
 
Dimethyl carbinol. 
 
Chemical name:  
 
Propan-2-ol. 
 
Empherical formula:  
 
C3H8O 
 
Molecular weight:  
 
60.1 
 
Structural formula:  
 
(CH3)2CHOH 
 
Category: 
 
Disinfectant, solvent. 
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Description:  
 
Clear, colorless, mobile, volatile flammable liquid with characteristic spirituous odor. 
Resembling that of a mixture of ethanol and acetone .It has slightly bitter taste. 
 
Solubility:  
 
It is miscible with Benzene, Chloroform, Ethanol, Glycerin and water. It is soluble in 
salt solutions. 
Incompatibility:  
 
It is incompatible with oxidizing agent such as hydrogen peroxide and nitric acid, 
which cause decomposition. It may be salted out from aqueous mixtures by the addition of 
sodium chloride, sodium sulphide and other salts or the addition of sodium hydroxide. 
 
Stability: 
  
Stored in air tight contains in a cool dry place. 
  
PURIFIED WATER42: It is a clear, colorless, odorless and tasteless liquid miscible in all 
polar solvents and widely used solvent vehicle for many formulations. 
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Table No: 1 
LIST OF MATERIALS 
 
 
 
 
 
 
 
S.NO Name of chemical Manufacturing company 
1 Viloxazine hydrochloride 
Gift sample from Lloyd pharma labs, 
Philippines. 
2 
Hydroxy propyl methyl cellulose 
K-100M 
S. D fine chem. Ltd., Mumbai 
3 Hydrogenated castor oil S. D fine chem. Ltd., Mumbai 
4 Ethyl cellulose 45cps S. D fine chem. Ltd., Mumbai 
5 Di calcium phosphate S. D fine chem. Ltd., Mumbai 
6 Poly vinyl pyrrolidone K-90 S. D fine chem. Ltd., Mumbai 
7 Iso propyl alcohol S. D fine chem. Ltd., Mumbai 
8 Magnesium stearate S. D fine chem. Ltd., Mumbai 
9 Aerosil S. D fine chem. Ltd., Mumbai 
10 Purified Talc  S. D fine chem. Ltd., Mumbai 
11 Acetone  S. D fine chem. Ltd., Mumbai 
12 Hydrochloric acid  S. D fine chem. Ltd., Mumbai 
13 Disodium hydrogen phosphate S. D fine chem. Ltd., Mumbai 
14 Potassium dihydrogen phosphate S. D fine chem. Ltd., Mumbai 
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Table No: 2 
LIST OF EQUIPMENTS 
S.No Name of Equipment Manufacturing company 
1 Electronic balance Remi Motors Ltd, Mumbai. 
2 Sonicator (bath) Enertech, Chennai. 
3 Magnetic stirrer Remi Motors Ltd, Mumbai. 
4 Tabletting machine Cadmach, Mumbai. 
5 Vernier calipers Digimatic calipers, Japan. 
6 Hardness tester Monsanto Mumbai. 
7 Friabilator Electrolab Mumbai. 
8 Dissolution apparatus Electrolab Mumbai. 
9 Hot air oven Minicon Mumbai. 
10 PH meter EL instruments Chennai. 
11 UV spectrometer Shimadzu, UV- 1601. 
12 High Performance Liquid 
Chromatography 
Shimadzu Prominence, LC 10AT 
(Pump) SPD10A (Detector). 
13 Fourier Transform Infrared 
Spectrometer 
AB.Bomem model no. MB 104, 
Canada. 
14 Centrifuge Remi equipments RM12C, Mumbai. 
15 Humidity cabinet Sigma instruments, Mumbai. 
16 Water bath Indian Scientific, Mumbai. 
17 Compression Machine Cadmach 20 Station, Ahmedabad. 
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IDENTIFICATION TEST FOR VILOXAZINE HCL40  
(Raw material evaluation) 
 
Description: 
 
 White to off white crystalline powder. 
 
Solubility: 
 
 Freely soluble in Acetic acid, Methanol, and in water. 
 
Melting point: 
 
 Viloxazine HCL melting point was fond to be 185-186°C using melting point 
apparatus. 
 
Percentage of purity: 
 
  Viloxazine HCL contains not less than 98% w/w and not more than 101%w/w 
calculated with reference to the anhydrous substance. 
 
A. It gives reaction (a) of chlorides. 
  
Tests:-  
 
Alkalinity or acidity:  
 
    Dissolve 0.20gm in carbon-di-oxide free water and dilute to 10ml with the same 
solvent .add 0.05ml of methyl red solution and 0.1ml of 0.01M HCl. The solution is pink, 
not more than 0.2ml of 0.01M NaOH is required to change the colour of the indicator to 
yellow. 
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Assay method by HPLC:  
 
pH 3.0 Buffer: Dissolve 3.4 gms of potassium di hydrogen phosphate anhydrous in 700ml 
of water, add 5ml of triethanolamine, mix well and adjust pH to 3.0 with phosphoric 
acid. 
 
Mobile phase: Mix pH3.0 buffer and acetonitrile in the ratio 70:30 v/v. 
Diluent: Methanol 
 
Standard preparation: Dissolve 58mg of Viloxazine hydrochloride in 50ml of diluent, 
pipette 5ml and dilute to 50ml with water (100ppm). 
 
Test preparation: Transfer the sample content equivalent 116mg of Viloxazine in 100ml 
flask, add 70ml of diluent and sonicate for 40mins dilute to volume with the same 
solvent and centrifuge or filter. 
 
Dilute 5ml of above solution to 50ml with water. 
 
HPLC conditions:  
 
      Wavelength:             220nm 
      Column:                   Princeton sphere C18, 250 x 4.6mm, 5µm 
      Flow Rate:                1.0ml/min 
      Column Temperature: Ambient 
      Injection volume:       40 µl 
      Run time:                   10min 
 
Identification of VILOXAZINE HCL by Infrared spectroscopy: 
 
 Comparison: If the spectra obtained in the solid state show differences, dissolve the 
substance to be examined and the reference substance separately in 2-propanol 
evaporates to dryness and record new spectra using the residues. 
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CALIBRATION GRAPH OF VILOXAZINE HYDROCHLORIDE IN 0.1 N HCl. 
 
Preparation of 0.1N HCl 
 
 Take 8.5ml of concentrated Hydrochloric acid in 1000 ml volumetric flask and 
make up the volume up to 1000ml with distilled water. 
 
Procedure for calibration graph 
 
 100 mg of Viloxazine hydrochloride was dissolved in 100 ml of   0.1 N HCl and 
further dilutions were made to obtain concentration ranging from 1 mcg/ml to 10mcg/ml. 
The absorbance of the solution were measured at 273 nm using SHIMADZU UV-Visible 
spectrophotometer .The readings obtained were recorded in Table No: 3   and graphically 
represented in Figure No: 3. 
 
LRA (Linear Regression Analysis) was performed to obtain equation for straight 
line. 
                           X = Y + 0.0038 / 0.0344 
Correlation coefficient was found to be 0.98 which when compared with given 
standard values is considered as best fit. 
CALIBRATION GRAPH OF VILOXAZINE HYDROCHLORIDE IN PHOSPHATE 
BUFFER pH 6.8 
 
Preparation of Phosphate buffer pH 6.8 
 
 Weigh accurately 28.80 gm of disodium hydrogen phosphate and   11.45 gm of 
potassium dihydrogen phosphate dissolved in distilled water and make up to 1000 ml with 
distilled water. 
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Procedure for calibration graph 
 100 mg of Viloxazine hydrochloride was dissolved in 100 ml of phosphate buffer 
pH 6.8 and further dilutions were made to obtain concentration ranging from 1 mcg/ml to 
10mcg/ml. the absorbance of the solution were measured at 273 nm using SHIMADZU 
UV-Visible spectrophotometer. The readings obtained were recorded in Table No: 4 and 
graphically represented in Figure No: 4.  
 
LRA (Linear Regression Analysis) was performed to obtain equation for straight 
line. 
                           X = Y - 0.005/.0503 
Correlation coefficient was found to be 1 which when compared with given 
standard values is considered as best fit.
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COMPATIBILITY BETWEEN DRUG AND OTHER TABLET 
COMPONENTS 
Viloxazine hydrochloride was mixed uniformly with different components used in 
formulation of tablet. The drug polymer mixture was kept under conditions of relative 
temperature 250-300C and relative humidity 75% for 70 days and the mixture was checked 
for any visible physical change and IR.  
    
The results are graphically represented in Figure No: 5, 6, 7 & 8. 
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FORMULATION OF MATRIX TABLETS 
 
All formulations were prepared according to Table no: 6.The tablets are prepared as 
per the procedure given below and aim is to sustain the release of Viloxazine 
hydrochloride. 
 
Procedure: 
 
1. Viloxazine hydrochloride, polymers (HPMC K100M, HCO, EC 45cps), Dicalcium 
phosphate were triturated well and allowed to pass through sieve no.30 and mixed 
thoroughly. 
 
2. Polyvinyl pyrollidone K-90 dissolved in Isopropyl alcohol was used as binder, the 
granules were prepared by wet granulation method after passing through sieve 
no.16. 
 
3. The granules thus obtained were dried at 60 0C. 
  
4.  The dried granules were passed through sieve no.16 and then added with the 
lubricants like talc, magnesium stearate and aerosil. 
 
5. The granules were compressed to get tablets of average weight 200 mg using 
double punching machine. 
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EVALUATION OF GRANULES43, 44 
 
The formulated Viloxazine hydrochloride granules were analyzed for its bulk 
density and flow properties. 
 
Bulk density: 
  
Bulk density is the ratio of weight of the powder to the bulk volume it occupies; 
expressed in gm/ml. 20 gm of the granules were weighed and poured into a 100ml-
measuring cylinder. This is called as bulk density or poured bulk density which is given as, 
 
          ρb    =        M 
                          Vb 
Where; 
 
 M = mass of granules. 
 Vb = bulk volume. 
 
Results are reproduced in Table No: 7. 
 
Angle of repose:   
 
The prepared granules were assessed for its flow property by determining the angle 
of repose. The angle of repose was measured by allowing the granules to fall over a graph 
paper placed on horizontal surface through a funnel. Kept at a certain convenient height 
about (6cm). The height of the heap was measured and then circumference of the base of 
heap was drawn on graph paper with the help of a pencil. The radius of the circle obtained 
was measured. 
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The angle of repose was given as, 
  
                              Tan θ = h / r 
                Where; 
 
                 θ – Angle of repose. 
                 h – Height of the heap. 
                 r – Radius of the base of the heap.    
 
The results are tabulated in the Table No: 7. 
 
Carr’s index: 
 
The percent compressibility of granules was determined by Carr’s compressibility 
index. 
 
Percent of Carr’s index =  
 
              [Tapped bulk density – poured bulk density] 
_____________________________________________ X 100 
                                [Tapped bulk density] 
 
 
Tapped bulk density = Mass of granules / tapped volume of packing 
 
Poured density = Mass of granules / volume of packing        
 
The results are tabulated in the Table No: 7. 
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EVALUATION OF THE TABLETS43, 44 
 
The formulated tablets were evaluated for the following physico chemical 
characteristics. 
 
General appearance: 
 
The formulated tablets were assessed for its general appearance. 
 
 Thickness and Diameter: 
 
Thickness and Diameter of the formulated matrix tablets were measured by using 
Vernier Calipers.  
The results were tabulated in Table No: 8. 
 
Weight variation: 
 
The formulated tablets were tested for weight uniformity. 20 tablets were weighed 
collectively and individually. From the collective weight, average weight was calculated. 
Each tablet weight was then compared with the average weight to ascertain whether it is 
within permissible limits or not.  
The results are tabulated in the Table No: 9 to13. 
 
Hardness: 
 
Hardness of the tablets was determined using the Monsanto hardness tester. The 
lower the plunger was placed in contact with the tablet and a zero reading was taken. The 
plunger was then forced against a spring by turning threaded bolt until the tablet fractured. 
As the spring was compressed a pointer rides along the gauge in the barrel to indicate the 
force. 
The results are tabulated in the Table No: 14. 
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Friability:  
 
The Roche friability test apparatus was used to determine the friability of the 
prepared tablets. 20 pre-weighed tablets were placed in the apparatus, which was given 100 
revolutions. After which the tablets were re-weighed. The percentage friability was 
calculated.  
 
Percentage of friability = 
 
(Pre-weight) – (post-weight) 
________________________ X 100 
               (Pre-weight) 
 
The results are tabulated in the Table No: 14. 
 
Drug content: 
 
Twenty tablets of each formulation were weighed and powdered. The quantity of 
powder equivalent to 40mg of Viloxazine was transferred into a 100ml volumetric flask 
and extracted with distilled water. Then it was filtered and suitable dilutions were made 
and absorbance was measured by using Shimadzu UV-Visible spectrophotometer (UV-
1601) at 273nm.  
 
The results were tabulated in Table No: 15. 
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In vitro dissolution studies of Viloxazine hydrochloride matrix tablets 
 
In Acid medium: 
 
900ml of 0.1N HCl was placed in a dissolution basket and the USP standard 
apparatus I was assembled. The medium was allowed to equilibrate to the temperature 37± 
0.5°C. 
 
One tablet was placed in the jar and the jar was covered with lid. The apparatus was 
operated for 2 hours at 100 rpm. At definite time intervals 5ml of the receptor fluid was 
withdrawn, suitable dilutions were made with 0.1N HCl and analyzed 
spectrophotometrically at 270 nm using SHIMADZU UV- Visible spectrophotometer.  
 
In buffer medium: 
 
900ml of phosphate buffer pH 6.8 was replaced in a dissolution basket which was 
prepared as per IP. The medium was allowed to equilibrate to the temperature 37± 0.5°C. 
 
 The tablets obtained after dissolution in acid stage were placed in the medium and 
dissolution was carried out at 100 rpm. At definite time intervals 5ml of the receptor fluid 
was withdrawn, suitable dilutions were made with phosphate buffer pH 6.8 and analyzed 
spectrophotometrically at 270nm using SHIMADZU UV- Visible spectrophotometer. The 
amount of drug released was calculated from the calibration curve.  
 
The results are shown in Table No.16-30 and graphically represented in Figure No: 
9-11. 
  
The same procedure is repeated for Viloxazine hydrochloride marketed SR tablet. 
The results are shown in Table No.31 and graphically represented in Figure No: 12. 
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Table No: 3 
Calibration data of Viloxazine Hydrochloride in  
0.1N Hydrochloric acid 
 
 
S. No 
Concentration 
(mcg/ml) 
Absorbance 
At 270nm 
1 1 0.044 
2 2 0.071 
3 3 0.105 
4 4 0.141 
5 5 0.174 
6 6 0.210 
7 7 0.244 
8 8 0.280 
9 9 0.315 
10 10 0.351 
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Table No: 4 
Calibration data of Viloxazine hydrochloride in 
Phosphate buffer pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No 
Concentration 
(mcg/ml) 
Absorbance 
At 270nm 
1 1 0.051 
2 2 0.102 
3 3 0.172 
4 4 0.200 
5 5 0.252 
6 6 0.305 
7 7 0.357 
8 8 0.405 
9 9 0.451 
10 10 0.515 
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Table No: 5 
Quantity Per Tablet (mg) 
Formulations 
S. 
No 
Ingredients I II III IV V VI VII VIII IX X XI XII XIII XIV XV 
1 Viloxazine HCl 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 
2 
Hydroxy propyl 
methyl cellulose, 
HPMC(k-100) 
12.50 25.00 37.50 50.00 62.50 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 
3 
Hydrogenated Castor 
Oil 
---- ---- ---- ---- ---- 12.50 25.00 37.50 50.00 62.50 ---- ---- ---- ---- ---- 
4 Ethyl cellulose 45cps ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 12.50 25.00 37.50 50.00 62.50 
5 
Poly vinyl 
pyrrolidone(k-90) 
9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 9.00 
6 Dicalcium phosphate 116.50 104.00 91.50 79.00 66.50 116.50 104.00 91.50 79.00 66.50 116.50 104.00 91.50 79.00 66.50 
7 Purified talc 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
8 Magnesium stearate 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 
9 Aerosil 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
10 Total 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00 
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Table No: 6 
DRUG POLYMER RATIOS  
 
 
 
 
S. No. Polymer Formulation Drug : Polymer 
1. 
Hydroxy propyl methyl 
cellulose 
K-100M 
F I 1:0.25 
2. F II 1:0.50 
3. F III 1:0.75 
4. F IV 1:1.00 
5. F V 1:1.25 
6. 
Hydrogenated castor oil 
F VI 1:0.25 
7. F VII 1:0.50 
8. F VIII 1:0.75 
9. F IX 1:1.00 
10. F X 1:1.25 
11. 
Ethyl cellulose 
45cps 
 
F XI 1:0.25 
12. F XII 1:0.50 
13. F XIII 1:0.75 
14. F XIV 1:1.00 
15. F XV 1:1.25 
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Table No: 7 
EVALUATION OF GRANULES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limits: Angle of Repose   ≈ 25-30° indicates free flowing material 
  Carr’s index    5-15% indicates free flowing material 
S.NO Formulation 
Angle of 
Repose 
 
Bulk Density 
Carr’s index 
1 F-I 29.25 0.47 7.57 
2 F-II 25.64 0.45 7.87 
3 F-III 28.81 0.43 8.24 
4 F-IV 27.92 0.46 8.33 
5 F-V 27.92 0.44 9.73 
6 F-VI 29.25 0.51 7.63 
7 F-VII 29.25 0.52 7.81 
8 F-VIII 28.37 0.53 8.78 
9 F-IX 27.92 0.54 7.59 
10 F-X 27.92 0.50 7.21 
11 F-XI 26.57 0.51 8.91 
12 F-XII 27.92 0.48 9.11 
13 F-XIII 29.25 0.49 8.40 
14 F-XIV 27.02 0.48 9.03 
15 F-XV 27.92 0.52 8.31 
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Table No: 8  
THICKNESS AND DIAMETER MEASUREMENT 
 
 
 
 
 
 
 
 
 
S.NO Formulations 
Thickness 
mm 
Diameter 
mm 
1 F-I 3.2 8.0 
2 F-II 3.5 8.4 
3 F-III 3.4 8.2 
4 F-IV 3.2 8.1 
5 F-V 3.6 8.3 
6 F-VI 3.6 8.5 
7 F-VII 3.3 7.8 
8 F-VIII 3.4 7.9 
9 F-IX 3.3 8.0 
10 F-X 3.3 8.5 
11 F-XI 3.6 8.6 
12 F-XII 3.4 8.5 
13 F-XIII 3.2 8.2 
14 F-XIV 3.5 7.9 
15 F-XV 3.4 8.3 
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Table No: 9 
UNIFORMITY OF WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
I.P Limits: Weight variation should not vary beyond ±7.5 % of standard value. 
S.NO 
Formulation-I Formulation-II Formulation-III 
Weight Of Each 
Tablet(mg) 
Percentage Deviation Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
1 203 1.0956 201 0.2493 202 0.4975 
2 200 -0.3984 200 -0.2493 200 -0.4975 
3 202 0.5976 200 -0.2493 201 0.0000 
4 205 2.9163 199 -0.7481 199 -0.9950 
5 199 -0.8964 201 0.2493 200 -0.4975 
6 200 -0.3984 202 0.7481 200 -0.4975 
7 203 1.0956 200 -0.2493 201 0.0000 
8 202 0.5976 202 0.7481 202 0.4975 
9 200 -0.3984 201 0.2493 200 -0.4975 
10 199 -0.8964 200 -0.2493 204 1.4925 
11 200 -0.3984 200 -0.2493 203 0.9950 
12 200 -0.3984 199 -0.7481 200 -0.4975 
13 201 0.0996 199 -0.7481 200 -0.4975 
14 200 -0.3984 203 1.2468 199 -0.9950 
15 202 0.5976 198 -1.2468 204 1.4925 
16 203 1.0956 201 0.2493 201 0.0000 
17 200 -0.3984 200 -0.2493 203 0.9950 
18 199 -0.8964 202 0.7481 200 -0.4975 
19 200 -0.3984 202 0.7481 200 -0.4975 
20 198 -1.3944 200 -0.2493 201 0.0000 
Average weight of 
Tablet 
200.8  200.5  201.0  
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Table No: 10 
UNIFORMITY OF WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.P Limits: Weight variation should not vary beyond ±7.5 % of standard value. 
S.NO 
Formulation-IV Formulation-V Formulation-VI 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
1 200 -0.099 201 0.149 200 -0.199 
2 203 1.398 200 -0.348 201 0.299 
3 201 0.399 200 -0.348 200 -0.199 
4 200 -0.099 199 -0.847 202 0.798 
5 199 -0.599 198 -1.345 198 -1.197 
6 200 -0.099 201 0.149 202 0.798 
7 197 -1.598 202 0.647 201 0.299 
8 199 -0.599 203 1.145 200 -0.199 
9 200 -0.099 202 0.647 198 -1.197 
10 205 2.397 200 -0.348 201 0.299 
11 199 -0.599 200 -0.348 200 -0.199 
12 200 -0.099 201 0.149 202 0.798 
13 201 0.399 198 -1.345 200 -0.199 
14 196 -2.097 203 1.145 201 0.299 
15 199 -0.599 202 0.647 200 -0.199 
16 202 0.899 202 0.647 200 -0.199 
17 202 0.899 200 0.348 200 -0.199 
18 200 -0.099 201 0.149 202 0.798 
19 200 -0.099 200 -0.348 202 0.798 
20 198 -1.098 201 0.149 198 -1.197 
Average weight of 
Tablet 
200.2  200.7  200.4  
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Table No: 11 
UNIFORMITY OF WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.P Limits: Weight variation should not vary beyond ±7.5 % of standard value. 
 
S.NO 
Formulation-VII Formulation-VIII Formulation-IX 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
1 201 0.199 201 0.349 200 -0.049 
2 200 -0.299 200 -0.149 202 0.949 
3 202 0.697 200 -0.149 201 0.449 
4 202 0.697 199 -0.649 199 -0.549 
5 199 -0.797 201 0.349 200 -0.049 
6 200 -0.299 202 0.848 200 -0.049 
7 201 0.199 200 -0.149 201 0.449 
8 202 0.697 201 0.349 202 0.949 
9 200 -0.299 203 1.347 200 -0.049 
10 199 -0.797 200 -0.149 199 -0.549 
11 200 -0.299 200 -0.149 198 -1.049 
12 200 -0.299 199 -0.649 200 -0.049 
13 201 0.199 199 -0.649 200 -0.049 
14 200 -0.299 203 1.347 199 -0.549 
15 202 0.697 198 -1.148 201 0.449 
16 203 1.196 201 0.349 198 -1.049 
17 200 -0.299 200 -0.149 201 0.449 
18 201 0.199 198 1.148 200 -0.049 
19 200 -0.299 201 0.349 200 -0.049 
20 199 -0.797 200 -0.149 201 0.449 
Average weight of 
Tablet 
200.6  200.3  200.1  
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Table No: 12 
UNIFORMITY OF WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.P Limits: Weight variation should not vary beyond ±7.5 % of standard value. 
S.NO 
Formulation-X Formulation-XI Formulation-XII 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
1 199 -0.500 200 0.050 199 -0.698 
2 201 0.500 201 0.550 200 -0.199 
3 200 0.000 200 0.050 200 -0.199 
4 200 0.000 200 0.050 199 -0.698 
5 199 -0.500 202 1.050 201 0.299 
6 200 0.000 201 0.550 199 -0.698 
7 201 0.500 203 1.550 203 1.297 
8 199 -0.500 200 0.050 201 0.299 
9 200 0.000 200 0.050 202 0.798 
10 200 0.000 200 0.050 202 0.798 
11 200 0.000 200 0.050 200 -0.199 
12 201 0.500 198 -0.950 200 -0.199 
13 199 -0.500 198 -0.950 200 -0.199 
14 202 1.000 201 0.550 199 -0.698 
15 198 -1.000 200 0.050 202 0.798 
16 202 1.000 199 -0.450 199 -0.698 
17 201 0.500 200 0.050 202 0.798 
18 200 0.000 195 -2.451 198 -1.197 
19 200 0.000 199 -0.450 202 0.798 
20 198 -1.000 201 0.550 200 -0.199 
Average weight 
of Tablet 
200.0  199.9  200.4  
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Table No: 13 
UNIFORMITY OF WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.P Limits: Weight variation should not vary beyond ±7.5 % of standard value. 
S.NO 
Formulation-XIII Formulation-XIV Formulation-XV 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
Weight Of Each 
Tablet(mg) 
Percentage 
Deviation 
1 200 -0.149 196 -2.000 201 0.249 
2 201 0.349 200 0.000 200 -0.249 
3 199 -0.649 201 0.500 202 0.748 
4 200 -0.149 201 0.500 201 0.249 
5 199 -0.649 200 0.000 201 0.249 
6 200 -0.149 199 -0.500 200 -0.249 
7 200 -0.149 200 0.000 199 -0.748 
8 202 0.848 200 0.000 200 -0.249 
9 201 0.349 197 -1.500 201 0.249 
10 201 0.349 201 0.500 199 -0.748 
11 202 0.848 200 0.000 201 0.249 
12 200 -0.149 203 1.500 202 0.748 
13 201 0.349 197 -1.500 200 -0.249 
14 198 -1.148 202 1.000 199 -0.748 
15 199 -0.649 199 -0.500 200 -0.249 
16 200 -0.149 203 1.500 201 0.249 
17 202 0.848 202 1.000 199 -0.748 
18 200 -0.149 199 -0.500 203 1.246 
19 200 -0.149 200 0.000 201 0.249 
20 201 0.349 200 0.000 200 -0.249 
Average weight 
of Tablet 
200.3  200.0  200.5  
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Table No: 14 
HARDNESS AND FRIABILITY 
 
 
 
Limits:  
 The hardness of about 50N is considered minimum for uncoated tablets. 
 Friability weight loss should not more than 1%. 
 
 
 
 
S.NO Formulation 
Percentage 
Friability 
Hardness 
(N) 
1 F-I 0.36 85 
2 F-II 0.41 90 
3 F-III 0.45 95 
4 F-IV 0.38 85 
5 F-V 0.42 90 
6 F-VI 0.54 90 
7 F-VII 0.48 85 
8 F-VIII 0.42 90 
9 F-IX 0.49 85 
10 F-X 0.61 90 
11 F-XI 0.31 85 
12 F-XII 0.42 90 
13 F-XIII 0.48 85 
14 F-XIV 0.36 95 
15 F-XV 0.45 90 
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Table No: 15 
DRUG CONTENT IN TABLETS 
 
 
S.NO 
 
Formulation 
Amount of drug (mg) in matrix tablets 
Sample1 Sample2 Sample3 Mean±S.D 
1 I 40.6 40.8 40.57 40.99±1.03 
2 II 40.5 40.3 39.25 39.35±1.82 
3 III 40.3 39.8 40.91 40.67±0.78 
4 IV 40.6 40.6 39.49 40.23±1.59 
5 V 40.1 40.7 40.53 40.11±0.86 
6 VI 40.9 40.6 40.15 40.55±0.83 
7 VII 40.9 39.5 40.29 40.23±0.70 
8 VIII 40.0 40.6 40.73 40.11±0.77 
9 IX 40.5 40.3 40.21 40.67±0.72 
10 X 40.5 40.6 39.27 39.79±1.32 
11 XI 40.8 40.8 39.41 40.67±1.20 
12 XII 39.4 40.6 40.69 40.23±0.72 
13 XIII 40.7 39.6 39.75 39.35±1.49 
14 XIV 40.1 39.9 39.37 39.79±0.38 
15 XV 40.2 40.6 40.53 40.11±0.79 
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Table No: 16  
In vitro drug release of formulation F I 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.115 3.23 14.55 34.64±0.41 
2 2 0.149 4.22 19.16 45.62±0.43 
3 3 0.046 0.82 23.03 54.85±0.50 
4 4 0.078 1.45 25.93 61.76±0.50 
5 5 0.113 2.15 29.14 69.39±0.53 
6 6 0.146 2.80 32.20 76.68±0.72 
7 7 0.178 3.44 35.20 83.83±0.62 
8 8 0.191 3.70 36.54 87.01±0.36 
9 9 0.193 3.74 36.90 87.88±0.09 
10 10 0.203 3.94 37.98 90.45±0.56 
11 11 0.206 4.00 38.45 91.56±0.37 
12 12 0.209 4.06 38.91 92.68±0.76 
13 24 0.209 4.06 39.12 93.16±0.22 
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Table No: 17 
In vitro drug release of formulation F II 
 
 
 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.096 2.68 12.06 30.65±0.4 
2 2 0.129 3.64 16.51 41.96±0.68 
3 3 0.056 1.01 19.69 50.03±0.20 
4 4 0.089 1.67 22.69 57.67±0.34 
5 5 0.126 2.41 26.09 66.29±0.60 
6 6 0.179 3.46 30.95 78.65±0.75 
7 7 0.193 3.74 32.37 82.27±0.44 
8 8 0.209 4.06 33.99 86.38±0.58 
9 9 0.221 4.29 35.27 89.62±0.73 
10 10 0.23 4.47 36.29 92.22±0.28 
11 11 0.23 4.47 36.51 92.78±0.41 
12 12 0.23 4.47 36.73 93.35±0.60 
13 24 0.231 4.49 37.05 94.15±0.45 
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Table No: 18 
In vitro drug release of formulation F III 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.085 2.36 10.62 26.12±0.45 
2 2 0.111 3.12 15.70 38.60±0.36 
3 3 0.035 0.60 18.84 46.31±0.59 
4 4 0.073 1.35 22.53 55.38±0.34 
5 5 0.092 1.73 24.33 59.81±0.44 
6 6 0.129 2.47 28.06 68.99±0.33 
7 7 0.152 2.92 30.40 74.75±0.60 
8 8 0.163 3.14 31.56 77.59±0.40 
9 9 0.182 3.52 33.48 82.32±0.30 
10 10 0.194 3.76 34.70 85.32±0.33 
11 11 0.205 3.98 35.82 88.09±0.43 
12 12 0.209 4.06 36.25 89.12±0.44 
13 24 0.225 4.37 37.85 93.07±0.52 
 
 
 
 
74 
 
Table No: 19 
In vitro drug release of formulation F IV 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.058 1.58 7.09 17.62±0.32 
2 2 0.078 2.16 10.86 27.00±0.46 
3 3 0.035 0.60 13.95 34.67±0.39 
4 4 0.073 1.35 17.76 44.14±0.38 
5 5 0.097 1.83 20.21 50.23±0.26 
6 6 0.121 2.31 22.69 56.39±0.22 
7 7 0.139 2.66 24.31 60.42±0.21 
8 8 0.158 3.04 26.50 65.88±0.57 
9 9 0.177 3.42 28.62 71.15±0.78 
10 10 0.197 3.82 30.74 76.42±0.33 
11 11 0.215 4.17 32.70 81.29±0.73 
12 12 0.225 4.37 33.88 84.22±0.38 
13 24 0.278 5.43 39.48 98.14±0.36 
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Table No: 20 
In vitro drug release of formulation F V 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.033 0.85 3.82 9.29±0.40 
2 2 0.056 1.52 6.87 16.71±0.52 
3 3 0.039 0.68 9.47 23.04±0.38 
4 4 0.075 1.39 12.72 30.95±0.31 
5 5 0.111 2.11 16.01 38.96±0.61 
6 6 0.139 2.66 18.63 45.31±0.18 
7 7 0.185 3.58 22.87 55.64±0.48 
8 8 0.209 4.06 25.20 61.30±0.32 
9 9 0.239 4.65 28.09 68.32±0.48 
10 10 0.268 5.23 30.91 75.20±0.91 
11 11 0.279 5.45 32.16 78.23±0.24 
12 12 0.293 5.73 33.68 81.94±0.91 
13 24 0.352 6.90 39.25 95.47±0.79 
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Table No: 21  
In vitro drug release of formulation F VI 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.115 3.23 14.55 35.01±0.17 
2 2 0.135 3.81 17.32 42.14±0.47 
3 3 0.035 0.60 20.36 49.52±0.47 
4 4 0.075 1.39 23.96 58.29±0.79 
5 5 0.098 1.85 26.09 63.47±0.61 
6 6 0.129 2.47 28.96 70.44±0.62 
7 7 0.175 3.38 33.20 80.75±0.42 
8 8 0.205 3.98 36.05 87.69±0.81 
9 9 0.209 4.06 36.61 89.04±0.28 
10 10 0.211 4.10 36.99 89.97±0.70 
11 11 0.211 4.10 37.19 90.47±0.17 
12 12 0.211 4.10 37.40 90.97±0.36 
13 24 0.213 4.14 37.78 91.90±0.23 
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Table No: 22  
In vitro drug release of formulation F VII 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.095 2.65 11.93 29.66±0.49 
2 2 0.118 3.32 15.07 37.46±0.40 
3 3 0.041 0.72 18.46 45.88±0.31 
4 4 0.075 1.39 21.54 53.53±0.43 
5 5 0.103 1.95 24.11 59.93±0.62 
6 6 0.126 2.41 26.27 65.29±0.28 
7 7 0.171 3.30 30.41 75.60±0.41 
8 8 0.192 3.72 32.46 80.68±0.50 
9 9 0.211 4.10 34.34 85.36±0.65 
10 10 0.213 4.14 34.73 86.32±0.41 
11 11 0.215 4.17 35.11 87.28±0.73 
12 12 0.215 4.17 35.32 87.80±0.44 
13 24 0.225 4.37 36.42 90.54±0.45 
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Table No: 23  
In vitro drug release of formulation F VIII 
 
 
 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.085 2.36 10.62 25.84±0.39 
2 2 0.097 2.71 12.31 30.60±0.33 
3 3 0.032 0.54 14.86 36.94±0.52 
4 4 0.052 0.93 16.68 41.45±0.62 
5 5 0.089 1.67 20.03 49.79±0.27 
6 6 0.105 1.99 21.55 53.56±0.86 
7 7 0.141 2.70 24.87 61.81±0.21 
8 8 0.175 3.38 28.04 69.71±0.37 
9 9 0.201 3.90 30.54 75.91±0.49 
10 10 0.213 4.14 31.81 79.06±0.61 
11 11 0.215 4.17 32.19 80.02±0.31 
12 12 0.218 4.23 32.67 81.21±0.95 
13 24 0.258 5.03 36.46 90.63±0.76 
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Table No: 24  
In vitro drug release of formulation F IX 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.043 1.14 5.13 12.61±0.27 
2 2 0.068 1.87 8.46 20.79±0.55 
3 3 0.037 0.64 11.47 28.21±0.90 
4 4 0.068 1.25 14.28 35.11±0.28 
5 5 0.1 1.89 17.20 42.30±0.80 
6 6 0.121 2.31 19.18 47.15±0.65 
7 7 0.158 3.04 22.60 55.57±0.59 
8 8 0.198 3.84 26.33 64.75±0.48 
9 9 0.222 4.31 28.67 70.50±0.29 
10 10 0.236 4.59 30.14 74.11±0.47 
11 11 0.245 4.77 31.17 76.65±0.60 
12 12 0.258 5.03 32.58 80.10±0.61 
13 24 0.309 6.04 37.39 91.94±0.42 
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Table No: 25  
In vitro drug release of formulation F X 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.032 0.82 3.69 9.27±0.29 
2 2 0.052 1.40 6.35 15.95±0.41 
3 3 0.032 0.54 8.44 21.20±0.46 
4 4 0.068 1.25 11.68 29.36±0.20 
5 5 0.1 1.89 14.61 36.72±0.42 
6 6 0.121 2.31 16.58 41.68±0.25 
7 7 0.142 2.72 18.58 46.69±0.70 
8 8 0.198 3.84 23.72 59.62±0.28 
9 9 0.222 4.31 26.06 65.50±0.33 
10 10 0.245 4.77 28.34 71.21±0.99 
11 11 0.258 5.03 29.74 74.73±0.77 
12 12 0.271 5.29 31.15 78.29±0.34 
13 24 0.332 6.50 36.87 92.67±0.18 
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Table No: 26  
In vitro drug release of formulation F XI 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.096 2.68 12.06 29.66±0.50 
2 2 0.125 3.52 15.99 39.31±0.83 
3 3 0.037 0.64 19.02 46.77±0.64 
4 4 0.095 1.79 24.24 59.61±0.80 
5 5 0.132 2.52 27.64 67.97±0.96 
6 6 0.178 3.44 31.88 78.40±0.28 
7 7 0.211 4.10 35.01 86.08±0.25 
8 8 0.228 4.43 36.73 90.32±0.23 
9 9 0.231 4.49 37.22 91.53±0.23 
10 10 0.233 4.53 37.63 92.52±0.44 
11 11 0.234 4.55 37.94 93.30±0.04 
12 12 0.234 4.55 38.17 93.86±0.64 
13 24 0.235 4.57 38.49 94.64±0.60 
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Table No: 27  
In vitro drug release of formulation F XII 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.087 2.42 10.88 27.05±0.37 
2 2 0.105 2.94 13.36 33.21±0.68 
3 3 0.037 0.64 16.37 40.69±0.79 
4 4 0.067 1.23 19.09 47.44±0.18 
5 5 0.121 2.31 23.98 59.61±0.60 
6 6 0.142 2.72 25.97 64.56±0.62 
7 7 0.195 3.78 30.85 76.69±0.42 
8 8 0.231 4.49 34.26 85.16±0.55 
9 9 0.238 4.63 35.11 87.28±0.36 
10 10 0.241 4.69 35.61 88.52±0.34 
11 11 0.243 4.73 36.02 89.55±0.20 
12 12 0.244 4.75 36.35 90.36±0.26 
13 24 0.251 4.89 37.21 92.51±0.46 
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Table No: 28  
In vitro drug release of formulation F XIII 
 
 
 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.081 2.24 10.10 25.66±0.31 
2 2 0.101 2.83 12.83 32.60±0.07 
3 3 0.028 0.46 15.03 38.20±0.36 
4 4 0.051 0.91 17.11 43.49±0.53 
5 5 0.085 1.59 20.20 51.33±0.25 
6 6 0.125 2.39 23.86 60.63±0.11 
7 7 0.151 2.90 26.30 66.84±0.33 
8 8 0.173 3.34 28.42 72.21±0.41 
9 9 0.221 4.29 32.88 83.55±0.52 
10 10 0.241 4.69 34.88 88.64±0.16 
11 11 0.243 4.73 35.29 89.69±0.53 
12 12 0.244 4.75 35.62 90.52±0.42 
13 24 0.251 4.89 36.48 92.72±0.81 
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Table No: 29 
In vitro drug release of formulation F XIV 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.066 1.81 8.14 20.45±0.42 
2 2 0.088 2.45 11.10 27.91±0.65 
3 3 0.029 0.50 13.45 33.80±0.95 
4 4 0.065 1.19 16.62 41.76±0.79 
5 5 0.085 1.59 18.46 46.40±0.34 
6 6 0.125 2.39 22.12 55.60±0.56 
7 7 0.158 3.04 25.19 63.32±0.25 
8 8 0.193 3.74 28.48 71.57±0.53 
9 9 0.226 4.39 31.62 79.46±0.33 
10 10 0.248 4.83 33.80 84.96±0.53 
11 11 0.253 4.93 34.49 86.69±0.61 
12 12 0.256 4.99 35.01 87.98±0.46 
13 24 0.268 5.23 36.33 91.31±0.45 
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Table No: 30  
In vitro drug release of formulation F XV 
 
 
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.055 1.49 6.70 16.29±0.07 
2 2 0.076 2.10 9.52 23.16±0.99 
3 3 0.035 0.60 12.30 29.93±0.99 
4 4 0.069 1.27 15.37 37.40±0.32 
5 5 0.103 1.95 18.48 44.95±0.76 
6 6 0.131 2.50 21.08 51.28±0.06 
7 7 0.158 3.04 23.62 57.46±0.37 
8 8 0.193 3.74 26.91 65.45±0.27 
9 9 0.226 4.39 30.05 73.09±0.20 
10 10 0.248 4.83 32.23 78.41±0.46 
11 11 0.259 5.05 33.46 81.39±0.23 
12 12 0.272 5.31 34.87 84.83±0.54 
13 24 0.311 5.92 38.05 95. 62±0.80 
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        Table No: 31  
In vitro drug release of Marketed formulation 
  
  
 
S.No Time(hrs) Absorbance 
Concentration 
(mcg/ml) 
Cumulative 
release(mg) 
Cumulative 
Percentage 
drug 
release±SD 
1 1 0.051 1.37 6.17 15.35±0.43 
2 2 0.074 2.04 9.25 23.00±0.06 
3 3 0.042 0.74 12.73 31.64±0.59 
4 4 0.081 1.51 16.26 40.41±0.53 
5 5 0.105 1.99 18.48 45.93±0.28 
6 6 0.142 2.72 21.89 54.41±0.21 
7 7 0.169 3.26 24.44 60.75±0.15 
8 8 0.194 3.76 26.84 66.72±0.56 
9 9 0.219 4.25 29.26 72.74±0.1 
10 10 0.241 4.69 31.45 78.16±0.23 
11 11 0.265 5.17 33.83 84.08±0.13 
12 12 0.273 5.33 34.80 86.51±0.52 
13 24 0.314 6.14 38.74 96.29±0.15 
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Figure No: 3 
       CALIBRATION OF VILOXAZINE HYDROCHLORIDE  
IN 0.1N HCI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calibration of Viloxazine hydrochloride in 0.1N HCl
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Figure No: 4 
CALIBRATION OF VILOXAZINE HYDROCHLORIDE 
IN PHOSPHATE BUFFER pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calibration of Viloxazine hydrochloride in phosphate buffer pH 6.8
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Figure No: 5  
FT-IR spectrum of Viloxazine Hydrochloride 
 
 
 
 
 
 
 
 
 
 
 
DR.CEEAL ANALYTICAL LAB                                             Mode = 2 (Mid-IR)                                            
Sample Description: VILOXAZINE HCL                           
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Figure No: 6  
FT-IR spectrum of Viloxazine Hydrochloride with HPMC and other excipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 7 
IR spectrum of matrix tablet with Hydrogenated castor oil 
 
 
 
DR.CEEAL ANALYTICAL LAB                                          Mode = 2 (Mid-IR)                                       
Sample Description: VILOXAZINE HCL +HPMC+PVP-K30+DCP+ MG STERATE+AEROSIL+TALC                          
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Figure No: 7 
FT-IR spectrum of Viloxazine Hydrochloride with HCO and other excipients 
 
 
 
 
 
 
 
DR.CEEAL ANALYTICAL LAB                                         Mode = 2 (Mid-IR)                                 
Sample Description: VILOXAZINE HCL +HCO+PVP-K30+DCP+ MG STERATE+AEROSIL+TALC                          
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Figure No: 8  
FT-IR spectrum of Viloxazine Hydrochloride with EC and other excipients 
 
 
 
 
 
 
  
 
 
 
 
 
 
DR.CEEAL ANALYTICAL LAB                                     Mode = 2 (Mid-IR)                      
Sample Description: VILOXAZINE HCL +EC+PVP-K30+DCP+ MG STERATE+AEROSIL+TALC                          
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Figure No: 9 
 
 
IN VITRO DRUG RELEASE FROM MATRIX TABLETS 
PREPARED USING HPMC K-100M
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Figure No: 10 
 
 
 
IN VITRO DRUG RELEASE FROM MATRIX TABLETS PREPARED 
USING HCO
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Figure No: 11 
 
 
 
IN VITRO DRUG RELEASE FROM MATRIX TABLETS PREPARED 
USING EC
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Figure No: 12 
 
 
 
Comparative in vitro  drug release of F IV with marketed SR 
product
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RESULTS AND 
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RESULTS AND DISCUSSSION 
 
Identification of Viloxazine Hydrochloride was performed by FT-IR and other 
identification tests as per B.P. Viloxazine Hydrochloride was mixed with hydroxy 
propyl methyl cellulose, hydrogenated castor oil and ethyl cellulose separately in 1:1 
ratio and stored at different temperatures (25˚C, 35˚C, 40˚C) to study the Viloxazine 
Hydrochloride, hydroxy propyl methyl cellulose, hydrogenated castor oil and ethyl 
cellulose interactions. This was performed using FT-IR. Spectra obtained were showed 
no interactions between Viloxazine and hydroxy propyl methyl cellulose, Viloxazine 
and hydrogenated castor oil and Viloxazine and ethyl cellulose. No colour change was 
observed. Hence it was conclude that Viloxazine Hydrochloride is compatible with 
hydroxy propyl methyl cellulose, hydrogenated castor oil and ethyl cellulose.   
 
Formulations F-I to F-XV were prepared as per Table: 5. Granules were 
prepared by wet granulation method. The prepared granules were evaluated for bulk 
density, angle of repose and compressibility. 
 
Bulk density for all the formulations ranged between 0.43 to 0.54. The angle of 
repose for all formulations ranged between 25˚.64 to 29˚.25 the bulk density indicates 
good packing characters. The value of angle of repose (between 25˚-30˚) for all the 
formulation indicates good flow property. The value of Carr’s index for all the 
formulations ranged between 7.212-9.110. The value of Carr’s index (between 5-15%) 
indicates free flowing material.  
 
The granules were then compressed to tablets. The tablets were evaluated for 
uniformity of weight, hardness, friability, drug content and dissolution. 
 
The tablets prepared were white in color, oval shape. They were smooth, 
uniform and free from crack and chipping.  
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Thicknesses of all fabricated formulations are in the range of 3.2-3.6 mm and 
the values shown in Table no: 8. Weight variation was found with in specifications of 
I.P limits and the values shown in Table no: 9-13. The hardness of all fabricated 
formulations were in the range of   80 –95N 
 
Friability for all the formulations was in the range of 0.36-0.61. The value of 
hardness and percent friability indicates good handling property of prepared tablets. 
The results for the above parameters were found to be in the recommended range. 
 
  The results of drug content for all formulations were found to be between 
39.35 mg - 41.99 mg per tablet with ±S.D.  
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SUMMARY 
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SUMMARY 
 
Formulations containing different ratios of HPMC showing following drug 
release profiles  
 
FI and FII released more than 80% of drug at 7th hour, where as FIII, FIV and 
FV released more than 80% of drug at 9th, 11th and 12th hours respectively.  
 
In case of formulations containing hydrogenated castor oil FVI and FVII 
releases more than 80% of drug at 7th and 8th hour respectively. FVIII releases more 
than 80% of drug at 11th hour. Whereas FIX and FX releases more than 80% of drug at 
12th hour. 
 
   In case of formulations containing ethyl cellulose, FXI and FXII releases more 
than 80% of drug at 11th and 12th hours. Whereas FXIII, FXIV, FXV are releasing 
more than 80% of drug at 9th, 10th and 11th hours. 
 
Marketed sustained release formulation (Vivalan) the drug release is 96.29% in 24 
hours, where as our selected formulations FIV and FX releases 98.14% and 95.62% of 
drug in 24 hours respectively.  This shows similar drug release profiles with that of 
marketed formulation. Whereas formulations FX containing hydrophobic polymer 
Ethyl Cellulose so there are much chances of dose dumping when compared with that 
of formulation FIV which contains hydrophilic polymer Hydroxy Propyl Methyl 
Cellulose. 
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CONCLUSION 
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CONCLUSION 
 
From the results and discussions, amongst the 15 different formulations 
designated as FI ,FII ,FIII, FIV, FV ,FVI, FVII, FVIII, FIX, FX, FXI,  FXII, FXIII, FIV 
and FX the formulation FIV  was found to be the better formulation in terms of 
sustained release and maximum percentage drug release and results are comparable 
with that of the marketed formulation. 
  
To conclude, hydroxy propyl methyl cellulose at a concentration ratio of 1: 1 is 
suitable for preparing sustained release matrix tablets of Viloxazine hydrochloride. 
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